Patient Studies
Prof. Dr. Thomas Klockgether
Director of the Clinical Research,
Head of Clinical Research Bonn,
Group Leader
Venusberg-Campus 1, Gebäude 99
(ehemals Sigmund-Freud-Str. 27)
53127 Bonn
 +49 228 287-15736

Areas of investigation/research focus

Ataxias denote degenerative disorders of the cerebellum and spinal cord. We are performing large clinical studies that have the goal to build the basis for performing clinical trials. In an ongoing study of 300 risk persons for dominantly inherited spinocerebellar ataxia we found earliest functional abnormalities in mutation carriers up to 20 years before ataxia onset. In a long-term natural history study of more than 500 patients we quantitatively defined disease progression and identified factors that determine progression. Our biomarker work involves MRI studies, movement recording and measurements of biochemical markers. We completed an investigator-initiated phase III trial with acetylleucine.

The locus coeruleus which is the source of forebrain noradrenergic innervation undergoes early degeneration in Alzheimer's disease (AD). We have established a number of behavioral and phyiological paradigms which are supposed to be correlates of the functionality of the locus coeruleus-norepinephrine system. Studies in AD patients showed consistently diminished physiological responses in these paradigms. In order to demonstrate that they depend on noradrenergic transmission we currently perform a study with the ß-receptor antagonist propranolol in healthy subjects. The final goal is to use these paradigms as outcome markers in early clinical trials of noradrenergic compounds.

 more Infos

To better understand the functional interaction beween neocortex and hippocampus during memory formation, we are using electrical stimulation to modulate memory functions and ameliorate declining memory functions in patients with memory deficits. Current work is characterizing the phase synchronization of prefrontal and parietal regions during successful associative memory formation. This will provide a basis for further investigation of manipulating the phase synchronization of prefrontal and parietal regions using electrical stimulation and its impact on associative memory formation and subsequent memory performance.


Jacobi H, Tezenas du Montcel S, Bauer P, Giunti P, ..., Klockgether T. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015 Jan 01; 14:1101-8. doi: 10.1016/S1474-4422(15)00202-1
Jacobi H, Reetz K, Tezenas du Montcel S, Bauer P, Mariotti C, ..., Klockgether T. Prospective study of individuals at risk for spinocerebellar ataxia type 1, 2, 3 and 6 (RISCA): analysis of baseline data. Lancet Neurol. 2013 Jan 01; 12:650-8. doi: 10.1016/S1474- 4422(13)70104-2
Philipp Koch, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting, Per Hoffmann, Thomas Klockgether, Bernd O. Evert, Ullrich Wüllner, Oliver Brüstle. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011 Dec 21; 480:543-546. doi: 10.1038/nature10671
Schmitz-Hübsch T, Tezenas du Montcel S, Baliko L, Berciano J, Boesch S, …, Klockgether T. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006 Jan 01; 66:1717-20. doi: 10.1212/01.wnl.0000219042.60538.92
Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol. 1990 Jan 01; 28:539-46. doi: 10.1002/ana.410280411


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.